Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Induction and Maintenance in Untreated MCL
NCT04736914Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2021
- Primary completion
- Jan 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in mantle cell lymphoma (MCL), sponsored by Sun Yat-sen University. Started Jan 2021; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04736914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736914.